SummaryThe cancer antigen 19-9 (CA19-9) blood test is a useful biomarker for pancreatic cancer in certain situations but is not increased in a substantial percentage of patients. This article reports that glycan biomarkers related to CA19-9 are increased in subsets of pancreatic cancer patients with prevalence similar to CA19-9. The detection of a 3-biomarker panel of glycans resulted in improved diagnostic accuracy over CA19-9.

Many pancreatic cancers secrete glycoproteins and glycolipids that bear a glycan called *sialyl-Lewis A* (sLeA).[@bib1], [@bib2] The sLeA glycan forms the basis for the Food and Drug Administration--approved cancer antigen 19-9 (CA19-9) test, named after the monoclonal antibody first developed against the sLeA antigen.[@bib3] The test is used as an approximate indicator of extent of disease recurrence, but a problem with CA19-9 is that it is not increased in a substantial proportion of patients. By using a typical cut-off value of 37 U/mL, approximately 25%--35% of patients do not show increases,[@bib4] rendering the test inconclusive for the diagnosis or monitoring of cancer in many patients. However, the test is very specific for cancer at high cut-off values.[@bib4] Therefore, CA19-9 represents an important marker for pancreatic cancer and a good basis on which to build molecular indicators for cancer, but it needs to be improved. After many years of research since the discovery of CA19-9, a biomarker validated to perform better than CA19-9 for pancreatic cancer detection is not yet available. Identifying another marker to detect cancer among patients with low CA19-9 levels potentially could lead to an improved diagnostic test.

The sLeA glycan is part of a family of glycans called the Lewis antigens, named after the discoverer of a series of antigens found on red blood cells comprising a system of blood types. The Lewis glycans generally appear on the termini of oligosaccharides attached to both proteins and lipids. The common feature among the family members is a core N-acetyl-lactosamine (LacNAc), which is a disaccharide of galactose linked to N-acetylglucosamine. The monosaccharides fucose and sialic acid can be attached to the LacNAc in various linkages. A sulfate group also can be attached to the Galactose or N-Acetylglucosamine. In the normal pancreas, sLeA appears on the epithelial surfaces of the ducts, and in the cancerous pancreas, it can be heavily secreted into the lumen of the proliferating ducts.[@bib5] The increase of sLeA in the blood likely results from accumulation in the stroma followed by leakage into the capillaries or lymph.[@bib6] One reason for the lack of increases is genetics. A glycosyltransferase enzyme that is critical for the biosynthesis of sLeA, fucosyltransferase 3, is inactive in approximately 5% of the North American population as a result of homozygous mutations in the active part of the gene.[@bib7] But the cause of low CA19-9 levels is not clear for patients with wild-type fucosytransferase 3.

Other members of the Lewis glycans besides sLeA also appear both in the normal and cancerous pancreas. An isomer of sLeA called sialyl Lewis X (sLeX) is up-regulated in the tissue of some pancreatic cancers,[@bib8] and we[@bib9], [@bib10] and others[@bib11] found it increased in the circulation of many pancreatic cancer patients. Some patients have an increase in a glycan detected by the DUPAN-2 monoclonal antibody,[@bib12], [@bib13] identified primarily as type 1 sialyl-LacNAc,[@bib14], [@bib15] and our previous research also found indirect evidence for additional glycans by comparing patient increases between anti-sLeA antibodies with either broad or narrow specificity.[@bib15]

These observations raise the possibility that diversity exists between pancreatic cancers in the type of glycans they make and secrete into the blood. Potentially, a variety of glycans is secreted, with differences between individual cancers. Thus, to encompass the full range of pancreatic cancers, we may need to detect the various antigens that pancreatic cancers are expressing in addition to sLeA, and that are not normally increased under healthy or benign conditions. Assays to detect the additional cancer-associated glycans potentially could be used to identify a higher percentage of pancreatic cancer patients than sLeA alone. Therefore, in this research, we tested the hypothesis that certain glycans related to sLeA are increased in the plasma of pancreatic cancer patients and that they detect patients that have low levels of sLeA.

Materials and Methods {#sec1}
=====================

Human Plasma and Tissue Samples {#sec1.1}
-------------------------------

All collections took place at the University of Pittsburgh Medical Center after obtaining informed consent from the participants and before any surgical or medical procedures. The donors consisted of patients with pancreatic cancer, pancreatitis, or benign biliary obstruction, and from healthy subjects ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table 1](#tblS1){ref-type="table"}). Resectable cancer included stages I and II, and nonresectable cancer included stages III and IV. The pancreatitis patients were a mixture of chronic and acute, and the healthy subjects had no evidence of pancreatic, biliary, or liver disease. All blood samples (EDTA plasma) were collected according to the standard operating procedure from the Early Detection Research Network and were frozen at -70°C or colder within 4 hours of time of collection. Aliquots were shipped on dry ice and thawed no more than 3 times before analysis.

In addition, the Van Andel Research Institute Biospecimen Facility provided formalin-fixed, paraffin-embedded tissue from patients who underwent pancreatic resections at a regional hospital affiliate in Grand Rapids, Michigan. The Institutional Review Boards at the University of Pittsburgh Medical Center and the Van Andel Research Institute approved this research project (protocol \#12008).

Biological Reagents {#sec1.2}
-------------------

The buffers and biological solutions used in the microarray assays included the following: 1X phosphate-buffered saline (PBS) + 0.5% or 0.1% Tween-20 (PBST 0.5 or 0.1 ); 10× sample buffer (1× PBS + 1% Tween-20 + 1% Brij-35; Thermo Scientific, Rockford, IL); 4× IgG blocking cocktail (400 μg/mL each of mouse, sheep, and goat IgG, 800 μg/mL rabbit IgG in 1× PBS, antibodies from Jackson Immunoresearch, West Grove, PA); 10× protease inhibitor (Complete Tablet; Roche Applied Science, Indianapolis, IN); and 2× sample dilution buffer (2× sample buffer + 2× protease inhibitor + 2× IgG cocktail in 1× PBS).

The antibodies and lectins were acquired from various sources ([Supplementary Table 2](#tblS2){ref-type="table"}). The capture antibodies to be printed onto microarray slides were purified by dialysis (Slide-A-Lyzer; Pierce Biotechnology, Rockford, IL) to 1× PBS and ultracentrifuged. Biotinylation was performed using the EZ-Link-sulfo-NHS-LC-Biotin kit (Pierce Biotechnology) according to the manufacturer's instructions.

Antibody Array Fabrication and Use {#sec1.3}
----------------------------------

The antibody array methods followed those presented earlier,[@bib16], [@bib17], [@bib18] with slight modifications. We printed 48 identical arrays containing various antibodies ([Supplementary Table 2](#tblS2){ref-type="table"}) onto glass microscope slides coated with ultra-thin nitrocellulose (PATH Slides; Grace BioLabs, Bend, OR) using a contact printer (Aushon 2470; Aushon BioSystems, Billerica, MA). We printed 6 replicates of each antibody in randomized positions within each array. After printing, hydrophobic borders were imprinted onto the slides (SlideImprinter; The Gel Company, San Francisco, CA) to segregate the arrays and allow for individual sample incubations on each array. The arrays were blocked using 1% bovine serum albumin (BSA) in PBS plus 0.5% Tween-20 for 1 hour at room temperature. The slides were rinsed in 1× PBS plus 0.5% Tween-20, washed in the same buffer for 15 minutes, and dried by brief centrifugation at 160 × g, with printed arrays facing outside.

The plasma samples were diluted 2-fold into PBS containing 0.1% Tween-20, 0.1% Brij-35, an IgG blocking cocktail (200 μg/mL mouse and rabbit IgG and 100 μg/mL goat and sheep IgG; Jackson ImmunoResearch), and protease inhibitor (Complete Mini EDTA-free Tablet, Roche Applied Science). We applied 6 μL of each plasma sample to each array and let the sample incubate overnight at 4°C. Each unique sample was applied to 3 separate arrays. The arrays were washed in 3 changes of PBS/0.1% Tween-20 for 3 minutes each and dried by centrifugation (Eppendorf 5810R, Hauppauge, NY rotor A-4-62, 1500 × g for 3 minutes), and a biotinylated lectin or antibody was incubated on the arrays for 1 hour at room temperature. The lectins and antibodies were prepared at 3 μg/mL in PBS with 0.1% BSA and 0.1% Tween-20, except for the anti-LeA (clone 7LE) antibody, which was at 15 μg/mL. For *Coprinopsis cinerea* lectin 2 (CCL2) detection, we pre-incubated the CCL2 with Cy5-conjugated streptavidin at a 4:1 molar ratio as described.[@bib9]

After washing and drying the arrays as described earlier, Cy5-conjugated streptavidin (Roche Applied Science) prepared at 2 μg/mL in PBS with 0.1% BSA and 0.1% Tween-20 was incubated for 1 hour at room temperature, followed by a final wash and dry. The arrays detected with precomplexed CCL2/streptavidin required only a final wash and dry. We scanned the slides for fluorescence using 633-nm excitation (LS Reloaded; Tecan, San Jose, CA).

We quantified the resulting images using in-house software written in Matlab (version R2014a; Mathworks, Natick, MA). We used a custom script to remove any outliers from the 6 replicate spots according to the Grubbs test. The script calculates the Grubbs statistic for the spot farthest from the mean of the replicates and rejects the spot if the Grubbs statistic exceeds a preset threshold, using *P* \< .1 here. The script repeatedly removes spots until no outliers remain or to a minimum of 4 spots. It then calculates the geometric mean of the remaining replicate spots as the final output for each array.

The program also averages values between replicate arrays and reports the associated coefficient of variation. We repeated assays for measurements that had a CV greater than 0.4 for signals in the quantifiable response range of the assay (determined by dilution series of pooled samples).[@bib19]

Statistics and Analysis Methods {#sec1.4}
-------------------------------

To characterize classification performance of individual biomarkers, nonparametric estimates of the receiver operating characteristic (ROC) curves were generated. Performance of each biomarker was compared with CA19-9 based on the area under the ROC curve (AUC). In particular, a nonparametric bootstrap procedure stratified on case and control status was performed with 500 bootstrap samples. Two-sided *P* values for testing the equivalence in AUC between a pair of biomarkers were computed based on a Wald test and bootstrap estimated standard error. Also reported were 95% confidence intervals of the difference in AUC based on bootstrap samples. All statistical calculations were performed using R program R-3.2.2 (<https://cran.r-project.org/>).

We selected marker panels using the Marker State Space method[@bib20] with 10-fold cross-validation to select individual markers. The program limits the initial size of panels to 3 markers, with the option of adding markers iteratively. Marker State Space software is available upon request. We used GraphPad Prism (San Diego, CA) and Microsoft (Redmond, WA) Excel for graph preparation, and Canvas XIV (ACD Systems, Victoria, Canada) for figure preparation.

Immunohistochemistry, Glycan Array Analysis, and Cross-Validation {#sec1.5}
-----------------------------------------------------------------

See [Supplementary Materials and Methods](#appsec1){ref-type="sec"} for more detail.

Results {#sec2}
=======

Candidate Glycan Biomarkers for sLeA-Low Cancers {#sec2.1}
------------------------------------------------

Several glycans are structurally similar to the CA19-9 antigen, sLeA ([Figure 1](#fig1){ref-type="fig"}*A*), including variants of sialyl-Lewis X, which we previously showed was increased in a subset of pancreatic cancer patients.[@bib9], [@bib10] To test for increases of glycans, we acquired lectins and antibodies targeting the glycans ([Figure 1](#fig1){ref-type="fig"}*B* and [Supplementary Table 2](#tblS2){ref-type="table"}). Glycan array data were helpful for determining the specificities of the reagents. Some bind only 1 motif with high specificity, but others bind more, such as the 7LE antibody, which binds both Lewis A and nonfucosylated LacNAc type 1 ([Supplementary Figure 1](#figS1){ref-type="fig"}). The mouse E-selectin protein binds sLeA, sLeX, and sulfo-sLeX ([Supplementary Figure 2](#figS2){ref-type="fig"}), and we validated its use as a detection reagent using cell line and tissue specimens ([Supplementary Figure 3](#figS3){ref-type="fig"}). We previously showed that CCL2 is specific for glycans with 3' fucose,[@bib9] mainly Lewis X variants including sulfated Lewis X.

We incubated each plasma sample on a microarray of antibodies targeting various mucins and glycans and then probed the glycans on the captured material with a glycan-binding antibody or lectin. Each sample was incubated on multiple arrays, with each array receiving a different detection reagent ([Figure 1](#fig1){ref-type="fig"}*C*).

We did not have a reagent to optimally detect sialylated, nonfucosylated, type 1 N-acetyl-lactosamine structures (Siaα2,3Galβ1,3GlcNAcβ1-). We did, however, have 2 antibodies, called *TRA-1-60* and *7LE* ([Figure 1](#fig1){ref-type="fig"}*B*), with good affinity to the nonsialylated variant. We therefore tested the use of sialidase to remove sialic acid before detecting with the antibodies ([Figure 2](#fig2){ref-type="fig"}*A*). We confirmed the ability to remove sialic acid on a captured glycoprotein and detect the underlying structure using a protein mixture with a high level of Mucin16 showing the sLeA glycan ([Figure 2](#fig2){ref-type="fig"}*B*). The staining of tumor tissue in the regions of cancerous epithelia increased upon sialidase treatment ([Figure 2](#fig2){ref-type="fig"}*D*), and the differentiation of cases from controls in a set of plasma samples was enhanced after enzyme treatment ([Figure 2](#fig2){ref-type="fig"}*C*). Therefore, in subsequent experiments we used sialidase treatment before detection using the TRA-1-60 and 7LE antibodies.

We acquired measurements of candidate biomarkers in 3 sample cohorts, comprising discovery, validation, and test sets ([Table 1](#tbl1){ref-type="table"} and [Supplementary Table 1](#tblS1){ref-type="table"}). Each measurement consisted of a capture antibody and a detection reagent, so with 9 capture antibodies and 12 detection reagents ([Supplementary Table 2](#tblS2){ref-type="table"}), we acquired 108 unique measurements of capture/detection pairs.

In the discovery cohort, 34 individual biomarkers had significant increases ([Supplementary Table 3](#tblS3){ref-type="table"}). Representative markers included 2 distinct glycoforms of MUC5AC, one showing type 1 sialyl-LacNAc, and the other showing sulfated and/or sialylated sLeA/sLeX ([Figure 3](#fig3){ref-type="fig"}*A*). We tested a reduced set of 5 capture antibodies and 5 detection reagents (25 unique assays) in the validation cohort and observed significant increases in 19 ([Supplementary Table 3](#tblS3){ref-type="table"}), including the glycoforms of MUC5AC ([Figure 3](#fig3){ref-type="fig"}*B*). The markers mentioned earlier showed significant improvement in AUC over sLeA in the discovery set ([Figure 3](#fig3){ref-type="fig"}*C*). The classification performance of sLeA in the validation set ([Figure 3](#fig3){ref-type="fig"}*D*) was higher than in previous studies. A recent definitive characterization of CA19-9 showed an AUC of 0.77 for discriminating pancreatic cancer from chronic pancreatitis, with lower performance when including benign biliary obstruction,[@bib21] so we viewed the performance in the validation set as an aberration.

Because the cancer patients tended to be older than the control subjects ([Table 1](#tbl1){ref-type="table"}), we tested associations with age for each marker within the cancer patients and within the control subjects. None showed an association with age except for the sLeA sandwich (the standard CA19-9 assay), with moderate significance ([Supplementary Table 4](#tblS4){ref-type="table"}). Thus, the markers examined here were not increased as a consequence of age.

Complementary Increases in the Markers {#sec2.2}
--------------------------------------

We next tested whether the individual markers provided complementary information to sLeA and to one another---that is, whether they showed increases in distinct subsets of patients and few increases in the controls. For each marker, we set a threshold to provide one false-positive increase, thus providing a view of increases that were specific to cancer. At such a threshold, CA19-9 was increased in only 22% of the cases in the discovery cohort. In contrast, several other markers showed a greater percentage of increases in the stages I--II and stages III--IV cancers, with differences between the markers in the patients with increases ([Figure 4](#fig4){ref-type="fig"}*A*). The trends were similar in the validation cohort ([Figure 4](#fig4){ref-type="fig"}*B*). These results suggested that the markers have increases in distinct groups of patients, independent of stage.

The results also suggested that a biomarker panel would perform better than any individual marker. By using all 316 samples from the combined discovery and validation cohorts, we found that a panel of 3 markers provided better sensitivity and specificity than sLeA ([Figure 4](#fig4){ref-type="fig"}*C*). The panel (panel 1) consisted of a glycoform of MUC5AC showing sulfated- and sialyl-Lewis X (detected by CCL2); another glycoform of MUC5AC showing sialyl-LacNAc type 1 and sLeA (detected by the 7LE antibody after desialylation); and a sandwich assay consisting of the capture of sLeA and the detection of sulfated and/or sialylated sLeA/sLeX (detected by mouse E-selectin). An alternate panel (panel 2) differed by 1 marker. The marker selection program did not choose sLeA for inclusion in the panel, indicating that sLeA at best provided only marginal additional diagnostic information beyond what already was detected by the 3 markers. A notable feature of the panel is that it contains 3 classes of glycans: Lewis X variants, Lewis A/X variants, and sialylated type 1 N-acetyl-lactosamine.

Testing the Marker Panel in Blinded Samples {#sec2.3}
-------------------------------------------

We applied the marker panels to a new, blinded set of 100 samples (ie, the test set), consisting of stages I--II cancer cases and patients with benign pancreatic diseases. The individual markers had robust and specific increases in cancer ([Figure 5](#fig5){ref-type="fig"}*A*), and the ROC curve for a MUC5AC glycoform was improved significantly compared with sLeA (with an improvement in AUC of 0.14; 95% confidence interval, 0.04--0.26) ([Figure 5](#fig5){ref-type="fig"}*B*). Furthermore, the relationships between the markers were similar to the previous sets; increases in the new markers occurred in patients who did not have sLeA increases ([Figure 5](#fig5){ref-type="fig"}*C*). These observations confirmed the cancer-associated increases of the new biomarkers and their independent contributions to the patterns of increase.

In the blinded application of the panels to classify the samples, both panels 1 and 2 had higher sensitivity than sLeA, but without statistically significant improvement in overall performance ([Supplementary Table 5](#tblS5){ref-type="table"}). We reasoned that the thresholds defining increases for each individual marker were not set optimally, owing to the limited number of samples used for training. When we adjusted the thresholds, while keeping the classification rule the same, the accuracy was 82% for panel 1 compared with 69% for sLeA at its best threshold. All 3 markers of the panel showed increases in cancer patient samples that were not increased in sLeA even at the lower sLeA threshold ([Figure 5](#fig5){ref-type="fig"}*D*). Furthermore, in 10-fold cross-validation averaged over 3 trials, the average accuracy of the panel was 84%, whereas the average accuracy of the individual markers ranged from 43% to 60% ([Figure 5](#fig5){ref-type="fig"}*D*). We concluded from these analyses that each of the new biomarkers was increased independently of sLeA at least in some patients, and that together they formed a biomarker panel with improved accuracy compared with sLeA.

Discussion {#sec3}
==========

In this work we identified glycan biomarkers in addition to the CA19-9 antigen, sLeA, that characterizes subgroups of pancreatic cancer patients. Because the glycans do not have identical increases across patients, they can be used in combination to provide better biomarker performance than any individual marker including sLeA. The glycans can be divided into 3 structural categories, consisting of sialyl-Lewis X variants, sulfated and/or sialylated sLeA/sLeX variants, and nonfucosylated sialyl-LacNAc type 1. Each category has its own biosynthetic pathways, cell types on which the glycans are shown, and protein receptors, suggesting that the glycans reflect biological subtypes of cancer. Thus, their combined use could have value not only for improved diagnostic accuracy, but also for enhanced information about the disease. Such a capability could meet the need for improved diagnostic accuracy among symptomatic people.[@bib22] Further research could address other needs in clinical practice, including surveillance among people with an increased risk for cancer, improving the determining likelihood of rapid progression after surgery, and monitoring the course of the disease after treatment.

Markers to subclassify pancreatic cancer cells would meet a gap in the application of molecular medicine to pancreatic cancer. Pancreatic cancers show huge diversity in histomorphologies and clinical courses, and finding a molecular basis for the differences has been difficult. For example, adenosquamous carcinomas harbor the same genetic mutations as the more common ductal adenocarcinomas.[@bib23] Particular glycans may be better molecular indicators of the state of a cell than specific genetic alterations; DNA alterations provide information about the inception of the neoplasm, but glycans may indicate changes more clearly in cell identity and cell-environment interactions. We previously found evidence that the tumors showing high sLeA were better differentiated than tumors with high sLeX,[@bib10] but a systematic study still is required to examine the molecular characteristics and clinical course of cancer cells showing the various glycans found here.

Additional research will help determine the relationship between the glycan biomarkers and other promising candidates for the detection of resectable and early stage pancreatic cancer. A recent study showed that exosomes coated with the proteoglycan glypican-1 were increased in patients with resectable pancreatic cancer and may represent a viable biomarker for early diagnosis or detection.[@bib24] Considering that the glycan side chains of glypican-1 are important in epithelial function and signaling, an interesting possibility is that the glycans found in the present work also are on cancer exosomes and could improve the information content of exosome detection. Other promising biomarkers include micro-RNAs,[@bib25] DNA,[@bib26] and tumor cells[@bib27] in the circulation; proteins in the urine[@bib28]; and various types of biomarkers in the pancreatic juice or stool (reviewed by Chari et al[@bib29]), all of which could help define biological subtypes of pancreatic cancer.

Previous studies have shown possible origins and functions in cancer of the glycans found in this work. Particularly interesting is sialyl-LacNAc type 1, as detected by the TRA-1-60 and 7LE antibodies after desialylation. The target of the TRA-1-60 antibody, the nonsialylated version of the glycan, is an excellent marker for pluripotent stem cells.[@bib30], [@bib31], [@bib32] Previous research found sialyl-LacNAc type 1 on glycolipids in malignant glioma[@bib33] and embryonal carcinoma.[@bib34] Pancreatic cancer cells frequently activate developmental pathways,[@bib35], [@bib36], [@bib37] potentially leading to the expression of the sialyl-LacNAc type 1 epitope. Future research could test whether cancer cells showing sLacNAc t1 have active sonic hedgehog, notch, or β-catenin pathways.

Sulfated and sialylated Lewis X is found on activated and migrating lymphocytes[@bib38], [@bib39] and are associated with an invasive phenotype in pancreatic cancer.[@bib40] Studies in mice support a role for sLeX in invasion and modulation of immune responses.[@bib41] Both sLeX and sLeA have the potential to promote metastasis through interactions with E-selectin receptors,[@bib42], [@bib43] therefore the relative levels of sLeX and sLeA could affect cancer cell behavior, disease progression, and metastasis. In future work we hope to define the glycan structures and the level of sulfation more precisely, because sulfated versions of sLeX have increased affinity for E-selectin receptors.[@bib42]

In summary, we show here that glycans besides sLeA---the antigen detected by the CA19-9 assay---are increased in distinct groups of patients and contribute to the improved accuracy of a biomarker panel. The 3 types of glycans---sLeA, sLeX variants, and sialylated type 1 LacNAc---possess structures and functions associated with particular differentiation states. Thus, the new glycan biomarkers have the potential to improve the accuracy of diagnosing pancreatic cancer and to shed light on the molecular differences between tumors.

Supplementary Materials and Methods {#appsec1}
===================================

Immunohistochemistry With Sialidase Treatment {#appsec1.1}
---------------------------------------------

We used automated staining (Ventana Discovery Ultra) to perform immunohistochemistry (IHC) on sections cut from formalin-fixed, paraffin-embedded blocks. We performed antigen retrieval using the Ventana CC1 buffer for 36 minutes at 95°C. For the slides treated with sialidase, we incubated a 1:200 dilution of sialidase (α2-3,6,8 Neuraminidase , NEB P0720L, 50,000 U/mL) in 1Χ GlycoBuffer (5 mmol/L CaCl~2~, 50 mmol/L pH 5.5 sodium acetate) overnight at 37°C. The control slides received only the 1× GlycoBuffer under the same conditions. The slides then were incubated with the TRA-1-60 antibody (NB100-730, Novus Biologicals, 500 ìg/mL diluted at 1:100) for 1 hour at RT, followed by the secondary antibody (Ventana Umap HRP-conjugated anti-mouse) for 12 minutes at 37°C. The development step used the diaminobenzadine chromagen according to preset parameters in the Ventana platform.

Glycan Array Analysis {#appsec1.2}
---------------------

The glycan synthesis and array core facility of the Consortium for Functional Glycomics (CFG) performed the glycan array experiments and the primary analysis according to the methods presented previously.[@bib27] We downloaded data from [www.functionalglycomics.org](http://www.functionalglycomics.org){#intref0015} that previously had been obtained using lectins and glycan-binding antibodies supplied by various investigators. In addition, we sent the recombinant version of CCL2 with biotinylation at the C-terminus to the CFG core facility for processing on their glycan array version 5.2. For detailed analyses of the datasets, we used the GlycoSearch analysis program,[@bib28] and for mining glycan array data to find particular lectins, we used the GlycanBinder database,[@bib23] which derives information from the CFG website.

Cross-Validation {#appsec1.3}
----------------

We performed 10-folded cross validation 3 times on each individual marker an on the panel, using the MSS program described in the main text. The program divides samples randomly into 10 groups; uses the samples from 9 groups to define optimal thresholds for discriminating cases from controls; and applies the thresholds to the remaining group to determine the accuracy of discrimination (calculated as the number of correct classifications divided by the total number of samples). The program repeats the process for each possible group of 9 (10 times in all), calculating an accuracy for each split and for each marker. For each marker, we averaged the accuracy over the 10 splits and over 3 repeats of the 10-fold cross validation.Supplementary Figure 1**Binding specificities of anti-Lewis A (clone 7LE) and anti-sialyl-Lewis A (clone 9L426).** The highlighted numbers are the relative fluorescence of the indicated lectins binding to the listed glycans, with the glycans grouped by motif. The red text in the glycan names indicates the sLeA motif, blue indicates nonfucosylated LacNAc type 1/type 2, and green indicates nonfucosylated LacNAc type 1. 7LE does not bind where sialic acid is present, but it does bind LacNAc type 1 without fucose. Anti-sLeA clone 9L426, on the other hand, mainly binds sLeA, but has weak binding when the fucose is missing. Neither antibody binds sialyl-Lewis X, shown at *bottom*.Supplementary Figure 2**Binding specificities of mouse and human E-selectin.** Both mouse and human E-selectins bind sLeA and sulfated Lewis A. Only the mouse E-selectin has high binding to sLeX, sulfo-sLeX, and sulfo-LeX (shown at *bottom*). Human E-selectin can bind disulfated LacNAc type 2 at a high lectin concentration.Supplementary Figure 3**Validation of mouse E-selectin (mSELE) as a detection reagent.** (*A*) Cell line microarray. We spotted lysates and conditioned media of cell lines known to express sLeA (BxPC3, Capan2, and Su8686) or to not express sLeA (BT20 and HEPG2), and probed the lysates with biotinylated mSELE followed by Cy5-labeled streptavidin. The fluorescence values show binding mainly on the cell lines expressing sLeA. (*B*) Antibody-lectin sandwich arrays. We spotted anti-sLeA, incubated dilutions of a lysate from BxPC3, and probed with mSELE. The fluorescence shows a good response curve with low nonspecific binding at the spot incubated with PBS. (*C*) Validation in immunofluorescence. Cy3-labeled anti-MUC5AC (green), Cy5-labeled mESEL (red), and 4′,6-diamidino-2-phenylindole (blue) were incubated on sections of pancreatic cancer (*top*) and adjacent control tissue (*bottom*). E-selectin binding appears on various proteins near the cancer cells, as expected.Supplementary Table 1Details of Sample CharacteristicsIDsSetDiseaseDiagnosisStageSexAge, *y*S05093Discovery1 pancreatic adenocarcinoma1Male76S05094Discovery1 pancreatic adenocarcinoma14Female59S05097Discovery1 pancreatic adenocarcinoma12Female78S05098Discovery1 pancreatic adenocarcinoma14Male79S05099Discovery1 pancreatic adenocarcinoma14Female57S05100Discovery1 pancreatic adenocarcinoma12Female86S05101Discovery1 pancreatic adenocarcinoma12Male84S05102Discovery1 pancreatic adenocarcinoma12Female68S05104Discovery1 pancreatic adenocarcinoma12Male49S05106Discovery1 pancreatic adenocarcinoma12Male67S05107Discovery1 pancreatic adenocarcinoma12Male62S05108Discovery1 pancreatic adenocarcinoma14Male60S05109Discovery1 pancreatic adenocarcinoma14Male71S05112Discovery1 pancreatic adenocarcinoma12Female69S05113Discovery1 pancreatic adenocarcinoma12Male77S05114Discovery1 pancreatic adenocarcinoma12Female84S05115Discovery1 pancreatic adenocarcinoma14Female79S05116Discovery1 pancreatic adenocarcinoma13Male80S05117Discovery1 pancreatic adenocarcinoma13Female56S05118Discovery1 pancreatic adenocarcinoma1Female80S05119Discovery1 pancreatic adenocarcinoma1Male65S05120Discovery1 pancreatic adenocarcinoma14Female66S05121Discovery1 pancreatic adenocarcinoma13Male64S05122Discovery1 pancreatic adenocarcinoma13Male72S05123Discovery1 pancreatic adenocarcinoma13Female53S05124Discovery1 pancreatic adenocarcinoma12Female62S05125Discovery1 pancreatic adenocarcinoma12Male61S05126Discovery1 pancreatic adenocarcinoma/528 pseudopapillary tumor12Female65S05129Discovery1 pancreatic adenocarcinoma12Female56S05131Discovery1 pancreatic adenocarcinoma14Male74S05132Discovery1 pancreatic adenocarcinoma/11 common bile duct stones13Female56S05134Discovery1 pancreatic adenocarcinoma1Female82S05137Discovery1 pancreatic adenocarcinoma12Male66S05140Discovery1 pancreatic adenocarcinoma14Female49S05141Discovery1 pancreatic adenocarcinoma14Male78S05142Discovery1 pancreatic adenocarcinoma14Female67S05143Discovery1 pancreatic adenocarcinoma12Female72S05171Discovery1 pancreatic adenocarcinoma13Male53S05173Discovery1 pancreatic adenocarcinoma14Female88S05175Discovery1 pancreatic adenocarcinoma13Female71S05179Discovery1 pancreatic adenocarcinoma13Male79S05181Discovery1 pancreatic adenocarcinoma14Female65S05182Discovery1 pancreatic adenocarcinoma12Male60S05183Discovery1 pancreatic adenocarcinoma14Female82S05187Discovery1 pancreatic adenocarcinoma14Male71S05189Discovery1 pancreatic adenocarcinoma12Female67S05195Discovery1 pancreatic adenocarcinoma1Female57S05196Discovery1 pancreatic adenocarcinoma14Male79S05197Discovery1 pancreatic adenocarcinoma12Male78S05198Discovery1 pancreatic adenocarcinoma14Female71S05202Discovery1 pancreatic adenocarcinoma12Male74S05204Discovery1 pancreatic adenocarcinoma13Female72S05207Discovery1 pancreatic adenocarcinoma13Female71S05208Discovery1 pancreatic adenocarcinoma13Female83S05209Discovery521 intraductal papillary mucinous neoplasm degenerated into adenocarcinoma12Female65S05213Discovery1 pancreatic adenocarcinoma13Male64S05214Discovery1 pancreatic adenocarcinoma14Male56S05216Discovery1 pancreatic adenocarcinoma13Male54S05217Discovery1 pancreatic adenocarcinoma13Female80S05218Discovery1 pancreatic adenocarcinoma12Female82S05221Discovery1 pancreatic adenocarcinoma12Female76S05223Discovery1 pancreatic adenocarcinoma13Female69S05226Discovery1 pancreatic adenocarcinoma13Female65S05230Discovery1 pancreatic adenocarcinoma12Female72S05234Discovery1 pancreatic adenocarcinoma12Male67S05235Discovery1 pancreatic adenocarcinoma12Female52S05236Discovery1 pancreatic adenocarcinoma13Male74S05238Discovery1 pancreatic adenocarcinoma14Female72S05239Discovery1 pancreatic adenocarcinoma14Female65S05243Discovery1 pancreatic adenocarcinoma13Male66S05247Discovery1 pancreatic adenocarcinoma13Male70S05250Discovery1 pancreatic adenocarcinoma14Female74S05251Discovery1 pancreatic adenocarcinoma1Male52S05258Discovery1 pancreatic adenocarcinoma/9 unknown cyst (clinical)14Female57S05259Discovery1 pancreatic adenocarcinoma14Female81S05266Discovery1 pancreatic adenocarcinoma12Male62S05270Discovery1 pancreatic adenocarcinoma12Female67S05272Discovery1 pancreatic adenocarcinoma14Male60S05279Discovery1 pancreatic adenocarcinoma14Female79S05281Discovery1 pancreatic adenocarcinoma12Male66S05284Discovery1 pancreatic adenocarcinoma/5 intraductal papillary mucinous neoplasm (surgical)12Female74S05286Discovery1 pancreatic adenocarcinoma13Male37S05287Discovery1 pancreatic adenocarcinoma14Female64S05293Discovery1 pancreatic adenocarcinoma12Male63S05306Discovery1 pancreatic adenocarcinoma13Male57S05309Discovery1 pancreatic adenocarcinoma13Male57S05311Discovery1 pancreatic adenocarcinoma13Male74S05318Discovery1 pancreatic adenocarcinoma13Male67S05324Discovery1 pancreatic adenocarcinoma12Male69S05325Discovery1 pancreatic adenocarcinoma13Male86S05331Discovery1 pancreatic adenocarcinoma13Male63S05336Discovery1 pancreatic adenocarcinoma13Male52S05340Discovery1 pancreatic adenocarcinoma12Male79S05342Discovery1 pancreatic adenocarcinoma14Female59S05346Discovery1 pancreatic adenocarcinoma/55 intraductal papillary mucinous neoplasm (clinical)11Male65S05352Discovery1 pancreatic adenocarcinoma13Male72S05355Discovery1 pancreatic adenocarcinoma13Male58S05356Discovery1 pancreatic adenocarcinoma12Female56S05357Discovery1 pancreatic adenocarcinoma13Male65S05360Discovery1 pancreatic adenocarcinoma12Female55S05372Discovery1 pancreatic adenocarcinoma14Male69S05392Discovery1 pancreatic adenocarcinoma12Female79S05396Discovery1 pancreatic adenocarcinoma14Female70S05397Discovery1 pancreatic adenocarcinoma14Female70S05398Discovery1 pancreatic adenocarcinoma14Male73S05400Discovery1 pancreatic adenocarcinoma14Female65S05401Discovery1 pancreatic adenocarcinoma13Female76S05403Discovery1 pancreatic adenocarcinoma11Female79S05149Discovery10 acute pancreatitis0Male67S05151Discovery10 acute pancreatitis0Male43S05154Discovery10 acute pancreatitis0Female73S05156Discovery10 acute pancreatitis0Female53S05200Discovery10 acute pancreatitis0Male46S05215Discovery10 acute pancreatitis0Female50S05222Discovery10 acute pancreatitis0Male54S05233Discovery10 acute pancreatitis0Male70S05242Discovery10 acute pancreatitis0Male47S05257Discovery10 acute pancreatitis0Male56S05262Discovery10 acute pancreatitis0Male49S05267Discovery10 acute pancreatitis0Male55S05305Discovery10 acute pancreatitis0Male58S05332Discovery10 acute pancreatitis0Female53S05339Discovery10 acute pancreatitis0Male83S05361Discovery10 acute pancreatitis0Female76S05371Discovery10 acute pancreatitis0Female49S05399Discovery10 acute pancreatitis0Male57S05162Discovery11 common bile duct stones0Female66S05163Discovery11 common bile duct stones0Male72S05166Discovery11 common bile duct stones0Male69S05244Discovery11 common bile duct stones0Male71S05261Discovery11 common bile duct stones0Female87S05273Discovery11 common bile duct stones0Male82S05274Discovery11 common bile duct stones0Female75S05295Discovery11 common bile duct stones0Female36S05328Discovery11 common bile duct stones0Female64S05347Discovery11 common bile duct stones0Female35S05351Discovery11 common bile duct stones0Female81S05370Discovery11 common bile duct stones0Male55S05389Discovery11 common bile duct stones0Female21S05394Discovery11 common bile duct stones0Female82S05153Discovery14 benign stricture; biliary dilation0Female86S05240Discovery14 benign stricture; biliary dilation0Female74S05253Discovery14 benign stricture; biliary dilation0Female47S05283Discovery14 benign stricture; biliary dilation0Female77S05298Discovery14 benign stricture; biliary dilation0Male58S05307Discovery14 benign stricture; biliary dilation0Female84S05315Discovery14 benign stricture; biliary dilation0Male68S05326Discovery14 benign stricture; biliary dilation0Male52S05348Discovery14 benign stricture; biliary dilation0Female59S05353Discovery14 benign stricture; biliary dilation0Female53S05354Discovery14 benign stricture; biliary dilation0Female73S05369Discovery14 benign stricture; biliary dilation0Female38S05385Discovery14 benign stricture; biliary dilation0Female66S05406Discovery14 benign stricture; biliary dilation0Female60S05290Discovery14 benign stricture; biliary dilation/15 gallstones0Female52S05145Discovery14 benign stricture; biliary dilation/55 intraductal papillary mucinous neoplasm0Male38S05150Discovery3 chronic pancreatitis0Female54S05158Discovery3 chronic pancreatitis0Male76S05161Discovery3 chronic pancreatitis0Male30S05167Discovery3 chronic pancreatitis0Male51S05185Discovery3 chronic pancreatitis0Female60S05194Discovery3 chronic pancreatitis0Female33S05199Discovery3 chronic pancreatitis0Male41S05210Discovery3 chronic pancreatitis0Male81S05211Discovery3 chronic pancreatitis0Female40S05220Discovery3 chronic pancreatitis0Male50S05225Discovery3 chronic pancreatitis0Female51S05227Discovery3 chronic pancreatitis0Male46S05229Discovery3 chronic pancreatitis0Male52S05232Discovery3 chronic pancreatitis0Male44S05241Discovery3 chronic pancreatitis0Male58S05246Discovery3 chronic pancreatitis0Female56S05248Discovery3 chronic pancreatitis0Male65S05249Discovery3 chronic pancreatitis0Male57S05260Discovery3 chronic pancreatitis0Male55S05263Discovery3 chronic pancreatitis0Male37S05268Discovery3 chronic pancreatitis0Female76S05277Discovery3 chronic pancreatitis0Female46S05278Discovery3 chronic pancreatitis0Female70S05280Discovery3 chronic pancreatitis0Female39S05282Discovery3 chronic pancreatitis0Female44S05297Discovery3 chronic pancreatitis0Male59S05303Discovery3 chronic pancreatitis0Female77S05308Discovery3 chronic pancreatitis0Male40S05314Discovery3 chronic pancreatitis0Female42S05317Discovery3 chronic pancreatitis0Male70S05327Discovery3 chronic pancreatitis0Female73S05329Discovery3 chronic pancreatitis0Male67S05334Discovery3 chronic pancreatitis0Female73S05338Discovery3 chronic pancreatitis0Male67S05349Discovery3 chronic pancreatitis0Female29S05350Discovery3 chronic pancreatitis0Male45S05364Discovery3 chronic pancreatitis0Male58S05366Discovery3 chronic pancreatitis0Female55S05367Discovery3 chronic pancreatitis0Male45S05381Discovery3 chronic pancreatitis0Male28S05402Discovery3 chronic pancreatitis0Female42S05291Discovery3 chronic pancreatitis/15 gallstones0Male76S05254Discovery3 chronic pancreatitis/57 pseudocyst (clinical)0Female55S06059Test1 pancreatic adenocarcinoma12Male49S06061Test1 pancreatic adenocarcinoma12Male62S06062Test1 pancreatic adenocarcinoma12Female78S06063Test1 pancreatic adenocarcinoma12Female70S06064Test1 pancreatic adenocarcinoma12Male76S06066Test1 pancreatic adenocarcinoma12Male64S06067Test1 pancreatic adenocarcinoma12Female63S06068Test1 pancreatic adenocarcinoma12Female78S06072Test1 pancreatic adenocarcinoma12Male69S06074Test1 pancreatic adenocarcinoma12Male88S06081Test1 pancreatic adenocarcinoma12Female72S06082Test1 pancreatic adenocarcinoma12Male76S06085Test1 pancreatic adenocarcinoma12Female74S06087Test1 pancreatic adenocarcinoma12Female62S06088Test1 pancreatic adenocarcinoma12Male65S06089Test1 pancreatic adenocarcinoma12Female69S06090Test1 pancreatic adenocarcinoma12Male74S06091Test1 pancreatic adenocarcinoma11Male58S06092Test1 pancreatic adenocarcinoma12Male65S06095Test1 pancreatic adenocarcinoma12Male76S06096Test1 pancreatic adenocarcinoma12Male71S06097Test1 pancreatic adenocarcinoma11Male77S06099Test1 pancreatic adenocarcinoma12Male70S06100Test1 pancreatic adenocarcinoma12Female51S06103Test1 pancreatic adenocarcinoma12Female81S06107Test1 pancreatic adenocarcinoma12Female56S06108Test1 pancreatic adenocarcinoma12Female63S06109Test1 pancreatic adenocarcinoma12Female78S06111Test1 pancreatic adenocarcinoma12Female70S06112Test1 pancreatic adenocarcinoma12Male50S06115Test1 pancreatic adenocarcinoma12Male58S06116Test1 pancreatic adenocarcinoma12Female61S06117Test1 pancreatic adenocarcinoma12Female79S06119Test1 pancreatic adenocarcinoma12Male56S06121Test1 pancreatic adenocarcinoma12Male85S06122Test1 pancreatic adenocarcinoma11Male69S06127Test1 pancreatic adenocarcinoma12Female52S06128Test1 pancreatic adenocarcinoma12Female72S06135Test1 pancreatic adenocarcinoma12Female37S06136Test1 pancreatic adenocarcinoma12Male61S06137Test1 pancreatic adenocarcinoma12Female68S06140Test1 pancreatic adenocarcinoma12Female52S06143Test1 pancreatic adenocarcinoma12Female75S06145Test1 pancreatic adenocarcinoma12Male66S06146Test1 pancreatic adenocarcinoma12Female65S06147Test1 pancreatic adenocarcinoma12Female29S06148Test1 pancreatic adenocarcinoma12Male57S06153Test1 pancreatic adenocarcinoma12Female82S06155Test1 pancreatic adenocarcinoma12Female71S06158Test1 pancreatic adenocarcinoma12Female54S06069Test10 acute pancreatitis0Male63S06070Test10 acute pancreatitis0Male51S06071Test10 acute pancreatitis0Female75S06075Test10 acute pancreatitis0Female61S06076Test10 acute pancreatitis0Male68S06086Test10 acute pancreatitis0Female35S06098Test10 acute pancreatitis0Male63S06101Test10 acute pancreatitis0Female70S06102Test10 acute pancreatitis0Male34S06104Test10 acute pancreatitis0Female62S06106Test10 acute pancreatitis0Male82S06126Test10 acute pancreatitis0Male60S06149Test10 acute pancreatitis0Male56S06152Test10 acute pancreatitis0Male64S06156Test10 acute pancreatitis0Male42S06060Test14 benign stricture; biliary dilation0Female75S06073Test14 benign stricture; biliary dilation0Female77S06083Test14 benign stricture; biliary dilation0Female69S06084Test14 benign stricture; biliary dilation0Female41S06093Test14 benign stricture; biliary dilation0Male34S06094Test14 benign stricture; biliary dilation0Female58S06105Test14 benign stricture; biliary dilation0Male55S06129Test14 benign stricture; biliary dilation0Male62S06134Test14 benign stricture; biliary dilation0Female44S06142Test14 benign stricture; biliary dilation0Female85S06065Test20 abnormal imaging test (benign)0Female38S06077Test20 abnormal imaging test (benign)0Male57S06078Test20 abnormal imaging test (benign)0Female63S06079Test20 abnormal imaging test (benign)0Male56S06080Test20 abnormal imaging test (benign)0Female56S06139Test20 abnormal imaging test (benign)0Female75S06141Test20 abnormal imaging test (benign)0Female72S06144Test20 abnormal imaging test (benign)0Female56S06157Test20 abnormal imaging test (benign)0Female27S06154Test20 abnormal imaging test (benign)0Female50S06110Test3 chronic pancreatitis0Female52S06113Test3 chronic pancreatitis0Female58S06114Test3 chronic pancreatitis0Female71S06118Test3 chronic pancreatitis0Male75S06120Test3 chronic pancreatitis0Female67S06123Test3 chronic pancreatitis0Female61S06124Test3 chronic pancreatitis0Female36S06125Test3 chronic pancreatitis0Female84S06130Test3 chronic pancreatitis0Female90S06131Test3 chronic pancreatitis0Female35S06132Test3 chronic pancreatitis0Male59S06133Test3 chronic pancreatitis0Female59S06138Test3 chronic pancreatitis0Male63S06150Test3 chronic pancreatitis0Female70S06151Test3 chronic pancreatitis0Female75S05090Validation1 pancreatic adenocarcinoma12Male68S05091Validation1 pancreatic adenocarcinoma12Male66S05092Validation1 pancreatic adenocarcinoma12Male66S05095Validation1 pancreatic adenocarcinoma14Male71S05096Validation1 pancreatic adenocarcinoma13Female71S05395Validation1 pancreatic adenocarcinoma14Male53S05103Validation1 pancreatic adenocarcinoma14Female59S05105Validation1 pancreatic adenocarcinoma14Male74S05110Validation1 pancreatic adenocarcinoma14Male78S05111Validation1 pancreatic adenocarcinoma12Female82S05127Validation1 pancreatic adenocarcinoma14Male73S05128Validation1 pancreatic adenocarcinoma14Female63S05130Validation1 pancreatic adenocarcinoma12Male56S05133Validation1 pancreatic adenocarcinoma13Male65S05135Validation1 pancreatic adenocarcinoma13Male58S05136Validation1 pancreatic adenocarcinoma14Female82S05138Validation1 pancreatic adenocarcinoma14Male45S05139Validation1 pancreatic adenocarcinoma14Male45S05169Validation1 pancreatic adenocarcinoma12Male51S05172Validation1 pancreatic adenocarcinoma12Female51S05176Validation1 pancreatic adenocarcinoma14Male65S05174Validation1 pancreatic adenocarcinoma12Female80S05201Validation1 pancreatic adenocarcinoma14Female62S05180Validation1 pancreatic adenocarcinoma14Female70S05186Validation1 pancreatic adenocarcinoma12Female75S05191Validation1 pancreatic adenocarcinoma12Female75S05205Validation1 pancreatic adenocarcinoma12Female71S05271Validation2 neuroendocrine tumor1Male60S05192Validation1 pancreatic adenocarcinoma12Male78S05255Validation1 pancreatic adenocarcinoma12Female63S05299Validation1 pancreatic adenocarcinoma13Male70S05294Validation1 pancreatic adenocarcinoma14Male65S05212Validation1 pancreatic adenocarcinoma12Male71S05245Validation1 pancreatic adenocarcinoma12Male68S05219Validation1 pancreatic adenocarcinoma12Female76S05228Validation1 pancreatic adenocarcinoma12Male60S05237Validation1 pancreatic adenocarcinoma14Female60S05252Validation1 pancreatic adenocarcinoma12Male81S05296Validation1 pancreatic adenocarcinoma12Female59S05300Validation1 pancreatic adenocarcinoma12Female64S05301Validation1 pancreatic adenocarcinoma14Male53S05285Validation1 pancreatic adenocarcinoma14Male54S05323Validation1 pancreatic adenocarcinoma14Male72S05405Validation1 pancreatic adenocarcinoma13Female63S05322Validation1 pancreatic adenocarcinoma12Female71S05359Validation1 pancreatic adenocarcinoma13Male71S05363Validation1 pancreatic adenocarcinoma14Female64S05377Validation1 pancreatic adenocarcinoma14Male64S05148Validation10 acute pancreatitis0Male37S05157Validation10 acute pancreatitis0Male33S05275Validation10 acute pancreatitis0Female60S05302Validation10 acute pancreatitis0Female53S05310Validation10 acute pancreatitis0Male61S05313Validation10 acute pancreatitis0Male39S05316Validation10 acute pancreatitis0Male23S05188Validation11 common bile duct stones0Female58S05341Validation11 common bile duct stones0Female78S05393Validation11 common bile duct stones0Male48S05144Validation14 benign stricture; biliary dilation0Female65S05146Validation14 benign stricture; biliary dilation0Male73S05147Validation14 benign stricture; biliary dilation0Male23S05152Validation14 benign stricture; biliary dilation0Female70S05231Validation14 benign stricture; biliary dilation0Female63S05375Validation14 benign stricture; biliary dilation0Male57S05335Validation16 primary sclerosing cholangitis0Male75S05155Validation20 abnormal imaging test (benign)0Female65S05165Validation20 abnormal imaging test (benign)0Female59S05159Validation20 abnormal imaging test (benign)0Female59S05160Validation20 abnormal imaging test (benign)0Male46S05170Validation20 abnormal imaging test (benign)0Female58S05177Validation20 abnormal imaging test (benign)0Female56S05178Validation20 abnormal imaging test (benign)0Female75S05193Validation20 abnormal imaging test (benign)0Female42S05269Validation20 abnormal imaging test (benign)0Female67S05203Validation20 abnormal imaging test (benign)0Female28S05184Validation20 abnormal imaging test (benign)0Female90S05206Validation20 abnormal imaging test (benign)0Female73S05224Validation20 abnormal imaging test (benign)0Female43S05264Validation20 abnormal imaging test (benign)0Female55S05276Validation20 abnormal imaging test (benign)0Female48S05304Validation20 abnormal imaging test (benign)0Female73S05292Validation20 abnormal imaging test (benign)0Female32S05319Validation20 abnormal imaging test (benign)0Female54S05321Validation20 abnormal imaging test (benign)0Female67S05337Validation20 abnormal imaging test (benign)0Male56S05404Validation20 abnormal imaging test (benign)0Female32S05343Validation20 abnormal imaging test (benign)0Female43S05344Validation20 abnormal imaging test (benign)0Male61S05345Validation20 abnormal imaging test (benign)0Female44S05358Validation20 abnormal imaging test (benign)0Male51S05362Validation20 abnormal imaging test (benign)0Male65S05380Validation20 abnormal imaging test (benign)0Female56S05382Validation20 abnormal imaging test (benign)0Male52S05373Validation20 abnormal imaging test (benign)0Female64S05374Validation20 abnormal imaging test (benign)0Male41S05383Validation20 abnormal imaging test (benign)0Female30S05384Validation20 abnormal imaging test (benign)0Male56S05376Validation20 abnormal imaging test (benign)0Male69S05386Validation20 abnormal imaging test (benign)0Male42S05388Validation20 abnormal imaging test (benign)0Male74S05390Validation20 abnormal imaging test (benign)0Female54S05391Validation20 abnormal imaging test (benign)0Female20S05379Validation20 abnormal imaging test (benign)0Female45S05168Validation3 chronic pancreatitis0Male43S05256Validation3 chronic pancreatitis0Female43S05312Validation3 chronic pancreatitis0Female43S05330Validation3 chronic pancreatitis0Male57S05378Validation3 chronic pancreatitis0Male26S05164Validation5 intraductal papillary mucinous neoplasm (surgical)0Male64S05333Validation522 panc surgery (pathology showed chronic pancreatitis)0Male52S05265Validation55 intraductal papillary mucinous neoplasm (clinical)0Male53S05368Validation55 intraductal papillary mucinous neoplasm (clinical)0Female76S05387Validation55 intraductal papillary mucinous neoplasm (clinical)0Female83S05288Validation57 pseudocyst (clinical)0Female48S05289Validation57 pseudocyst (clinical)0Male65S05320Validation9 unknown cyst (clinical)0Female45S05365Validation9 unknown cyst (clinical)0Female68Supplementary Table 2Capture Antibodies and Detection ReagentsNameIDPrimary targetSourceCatalog No.Capture antibodies Anti-MUC1CM1MUC1GeneTex (Irvine, CA)GTX10114 Anti-MUC16X325MUC16Abcam (Cambridge, MA)AB10033 Anti-MUC16 (Ab2)X306MUC16Novus Biologicals (Littleton, CO)NB120-10032 Anti-MUC5AC45M1MUC5ACThermoScientific (Waltham, MA)MS-145-P1ABX Anti-MUC5AC (Ab2)2-11M1MUC5ACAffinity BioReagents (Golden, CO)MA1-35704 Anti-sialyl Lewis A (CA19-9, Ab1)9L426Sialyl Lewis AUSBio (Salem, MA)C0075-03A Anti-sialyl Lewis A (CA19-9, Ab2)121SLESialyl Lewis AAbcamAB3982 Anti-sialyl Lewis XCSLEX1Sialyl Lewis XBD Pharmingen (San Jose, CA)551344 Anti-Lewis XP12Lewis XAbcam3358 Mouse IgG, biotin labeledN/AN/AJackson ImmunoResearch (West Grove, PA)015-000-003Detection antibodies and lectins Anti-sialyl Lewis A (CA19-9, Ab1)9L426Sialyl Lewis AUSBioC0075-03A TRA-1-60TRA-1-60Terminal N-acetyl-lactosamine, type 1Novus BiologicalsNB100-730 Anti-sialyl Lewis XCSLEX1Sialyl Lewis XBD Pharmingen551344 DUPAN2DUPAN2Sialyl Lewis A and sialyl Lewis CDr Hollingsworth (Nebraska)N/A Recombinant mouse E-selectin/CD62E Fc chimera, CFESELSulfated Lewis structureR&D Systems (Minneapolis, MN)575-ES-100 Anti-blood group Lewis A7LELewis A and terminal N-acetyl-lactosamine, type 1Abcamab3967 Erythrina cristagalli lectinECLTerminal GalβVector Labs (Burlingame, CA)BK-3000 Helix aspersa agglutininHAATerminal GlcNAcα, GalNAcα, GalNAcβSigma-Aldrich (St. Louis, MO)L8764 Ricinus communis agglutinin IRCA-1Terminal galactoseVector LabsBK-1000 Ralstonia solanacearum lectinRSLαFucose, all linkagesRecombinant productionN/A Coprinopsis cinerea (Inky cap fungus) lectin 2CCL2Lewis X variants: sialylated, sulfated, internalRecombinant productionN/A Sclerotia rolfsii lectinSRLTerminal GlcNAcWako (Richmond, VA)199-17271 Bauhinea purpurea lectinBPLTerminal GalβVector LabsBK-1285Supplementary Table 3*P* Values of the Individual Assays in the Discovery and Validation CohortsAssayDiscoveryValidation*sLeA: sulfo/sLeX/sLeA(ESEL)6.06E-141.81E-04*MUC5AC: sulfo/sLeX/sLeA (ESEL)1.30E-111.44E-05sLeA: sLeA/sLacNAc t1 (7LE)8.62E-111.04E-06*MUC5AC: sulfo/sLeX (CCL2)3.66E-102.80E-05MUC5AC: sLeA/sLacNAc t1 (7LE)5.02E-106.46E-05*sLeX: sulfo/sLeX/sLeA (ESEL)9.01E-09NS**sLeA: sLeA1.02E-072.00E-03**MUC16: sulfo/sLeX/sLeA (ESEL)3.54E-077.58E-04MUC16: sLeA/sLacNAc t1 (7LE)1.17E-065.09E-04sLeA(Ab2): sLeA/sLacNAc t1 (7LE)5.45E-066.88E-05MUC16(Ab2): sulfo/sLeX/sLeA (ESEL)9.56E-06-LeA: sulfo/sLeX/sLeA (ESEL)1.73E-05-MUC16: sLeA3.29E-053.83E-02sLeA(Ab2): sLeA3.88E-056.45E-03sLeA(Ab2): sLacNAc t1t2 (TRA-1-60)5.76E-05NSsLeX: sulfo/sLeX (CCL2)5.90E-057.11E-05LeA: sLacNAc t1t2 (TRA-1-60)7.20E-05-sLeX: sLeA/sLacNAc t1 (7LE)9.54E-051.22E-03sLeA: sLacNAc t1t2 (TRA-1-60)1.05E-048.32E-03MUC5AC(Ab2): sulfo/sLeX/sLeA (ESEL)1.46E-04-MUC1: sLacNAc t1t2 (TRA-1-60)2.44E-04-sLeA: sLeX3.43E-045.09E-03sLeX: sLeX3.78E-04NSMUC16: sLacNAc t1t2 (TRA-1-60)7.66E-041.46E-02MUC16: sulfo/sLeX (CCL2)8.75E-045.78E-03sLeA: sulfo/sLeX (CCL2)1.19E-031.86E-04*MUC5AC: sLacNAc t1t2 (TRA-1-60)1.21E-034.93E-02*LeA: sLeX4.59E-03-MUC5AC(Ab2): sLacNAc t1t2 (TRA-1-60)1.23E-02-sLeX: sLacNAc t1t2 (TRA-1-60)1.81E-02NSsLeA(Ab2): sLeX3.42E-02NSLeX: sLacNAc t1t2 (TRA-1-60)3.79E-02-LeX: sulfo/sLeX/sLeA (ESEL)4.90E-02-[^1]Supplementary Table 4Associations Between Marker levels and Age Within Patient GroupsCohortYoung cancer patients vs oldYoung control patients vs oldDiscovery MUC5AC: sLacNAc t1t2 (TRA-1-60)NSNS sLeA: sulfo/sLeX/sLeA (ESEL)NSNS MUC5AC: sulfo/sLeX (CCL2)NSNS MUC5AC: sLeA/sLacNAc t1 (7LE)NSNS sLeA: sLeANSNSValidation MUC5AC: sLacNAc t1t2 (TRA-1-60)NSNS sLeA: sulfo/sLeX/sLeA (ESEL)NSNS MUC5AC: sulfo/sLeX (CCL2)NSNS MUC5AC: sLeA/sLacNAc t1 (7LE)NSNS sLeA: sLeANSNSTest MUC5AC: sLacNAc t1t2 (TRA-1-60)NSNS sLeA: sulfo/sLeX/sLeA (ESEL)NSNS MUC5AC: sulfo/sLeX (CCL2)NSNS MUC5AC: sLeA/sLacNAc t1 (7LE)NSNS sLeA: sLeANS*P* \< .05 (higher in older patients)[^2]Supplementary Table 5Performance of the Panels and sLeA in the Blinded SamplesPanelSensitivity*P* valueSpecificity*P* value(Sen+Spe)/2*P* valuesLeA:sLeA0.54 (0.40--0.67)0.84 (0.71--0.92)0.69 (0.60--0.77)Panel 10.66 (0.52--0.78)NS0.80 (0.67--0.89)NS0.73 (0.64--0.81)NSPanel 20.72 (0.58--0.83).020.70 (0.56--0.81).060.71 (0.61--0.79)NSsLeA:sLeA.66.72.69Panel 1.80.84.82Panel 2.76.80.78[^3]
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![**Testing candidate glycans related to sLeA.** (*A*) Glycans with structures similar to sLeA. (*B*) Reagents to detect the glycan structures. A *red square* indicates specificity for a glycan, and the *bolded boxes* indicate structures for which we had no detection reagent. (*C*) Antibody-lectin sandwich arrays for parallel testing of candidate biomarkers.](gr1){#fig1}

![**Using sialidase to expose underlying glycans.** (*A*) Treatment with sialidase to expose terminal, type 1 N-acetyl-lactosamine. (*B*) Sialidase treatment of captured MUC16 eliminated the sLeA epitope (*left*); exposed terminal galactose, as detected by the *Bauhinea purpurea* lectin (BPL, *middle*); and did not affect the amount of retained MUC16 (*right*). (*C*) Sialidase treatment resulted in increased staining of selected regions of cancer tissue by the TRA-1-60 antibody. (*D*) Sialidase treatment of captured MUC5AC in a series of plasma samples exposed the TRA-1-60 epitope and resulted in improved discrimination between cancer and control samples.](gr2){#fig2}

![**Novel glycan biomarkers of pancreatic cancer.** (*A*) Discovery cohort. The heading of each graph indicates the capture and detection targets, separated by a colon. A glycoform of MUC5AC showing type 1 sialyl-LacNAc (detected by TRA-1-60 after desialylation) and a sandwich assay of sLeA capture and sulfated and/or sialylated sLeA/sLeX detection (detected by mouse E-selectin) showed significant increases in cancer. (*B*) Validation cohort. We observed similar increases in the next set of samples. The receiver-operator characteristic curves showed (*C*) improvement over sLeA in the discovery cohort and (*D*) comparable performance in the validation cohort.](gr3){#fig3}

![**Complementary increases in early-stage and late-stage cancers.** (*A*) Discovery cohort. The *rows* present data from the indicated capture and detection targets, and the *columns* represent individual plasma samples. For each biomarker, we set a threshold to provide 1 increase in the control samples. A *red box* indicates a measurement greater than the threshold, and a *yellow box* is a measurement below the threshold. Several markers were increased at this high-specificity threshold in both stages I--II and stages III--IV patient samples, including samples without sLeA increases. (*B*) The validation samples showed similar patterns of increases. (*C*) Two candidate biomarker panels provided improved performance compared with sLeA in the combined sample sets.](gr4){#fig4}

![**Blinded testing of the individual and combined biomarkers.** (*A*) The individual assays showed increases similar to those observed in the previous cohorts. (*B*) The ROC curves were consistent with previous performance. The MUC5AC glycoform showing type 1 sLacNAc had significantly better performance than sLeA. (*C*) At high-specificity thresholds, the patterns of increase were similar to those in the previous cohorts. Several assays were increased in patient samples that were not increased in sLeA. (*D*) We classified a sample as a case if it showed an increase in at least 1 of the 3 markers. The *bottom row* indicates the classification, where blue is a case, and gray is a control. The average accuracy of the panel (calculated as correct classifications divided by the number of samples) in 10-fold cross-validation performed 3 times exceeded that of sLeA and any individual marker.](gr5){#fig5}

###### 

Sample Characteristics

  Discovery                                     N     Age, *y* (SD)   Male, *%*   Validation                                    N    Age, *y* (SD)   Male, *%*   Test                                          N    Age, *y* (SD)   Male, *%*
  --------------------------------------------- ----- --------------- ----------- --------------------------------------------- ---- --------------- ----------- --------------------------------------------- ---- --------------- -----------
  All cancer                                    108   68.1 (9.8)      48.1        All cancer                                    48   65.9 (9.3)      58.3        All cancer                                    50   66.1 (12.0)     46.0
   Stage I                                      2                                  Stage I                                      0                                 Stage I                                      3                    
   Stage II                                     36                                 Stage II                                     21                                Stage II                                     47                   
   Stage III                                    32                                 Stage III                                    6                                 Stage III                                    0                    
   Stage IV                                     32                                 Stage IV                                     20                                Stage IV                                     0                    
  Unknown stage                                 6                                 Unknown stage                                 0                                Unknown stage                                 0                    
  Neuroendocrine tumor                          0                                 Neuroendocrine tumor                          1                                Neuroendocrine tumor                          0                    
  All control                                   91    57.5 (15.3)     49.5        All control                                   69   54.0 (15.4)     40.6        All control                                   50   59.8 (14.8)     36.0
  Pancreatitis                                  61                                Pancreatitis                                  12                               Pancreatitis                                  30                   
  Benign stricture                              30                                Benign stricture                              9                                Benign stricture                              10                   
  Abnormal Imaging                              0                                 Abnormal Imaging                              48                               Abnormal Imaging                              10                   
  *P* value[a](#tbl1fna){ref-type="table-fn"}         \<.05           NS          *P* value[a](#tbl1fna){ref-type="table-fn"}        \<.05           NS          *P* value[a](#tbl1fna){ref-type="table-fn"}        \<.05           NS

*P* value was computed based on a 2-sample *t* test for continuous variables (age) and the Fisher exact test for binary variable (sex).

[^1]: NOTE. The assays that were in the biomarker panels are shown in italics, and the CA19-9 assay (capture and detection of sLeA) is shown in bold.

[^2]: NOTE. Within either just the cancers or just the controls, we divided the subjects by age, with the oldest third in one group and the youngest third in another group. We then compared the levels of each marker between the groups. Only one comparison showed a statistical difference.

[^3]: NOTE. Top: performance based on the blinded classifications; middle: *P* value of comparisons between the panels and the CA19-9 assay (capture and detection of sLeA); bottom: performance after adjusting the thresholds of the individual markers.
